Author

M. A. Davare

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. Keddy· 2 shared C. Z. Beach· 2 shared K. Jones· 2 shared K. Nusser· 2 shared A. Drilon· 1 shared E. Aguero· 1 shared G. Harada· 1 shared J. Force· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Keddy

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers

R. Thawani, M. Repetto, C. Keddy, K. Nicholson, K. Jones, K. Nusser, C. Z. Beach, G. Harada, A. Drilon, M. A. Davare

This study shows that type II TKIs cabozantinib and merestinib, and type I FLT3 inhibitor gilteritinib, inhibit ROS1 L2086F mutant kinase, overcoming resistance to type I TKIs in ROS1 fusion-positive cancers.

bioRxiv · Jan 16, 2024Cancer Biology

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

S. R. Iyer, K. Nusser, K. Jones, P. Shinde, C. Z. Beach, C. Keddy, E. Aguero, J. Force, U. Shinde, M. A. Davare

The paper identifies oncogenic ROS1 missense mutations that are sensitive to tyrosine kinase inhibitors, showing their potential as therapeutic targets.

EMBO Molecular Medicine · Oct 11, 2023Peer-reviewedCancer Biology